Clinical Trials Browser

Lymphoma, B-Cell × polatuzumab vedotin × 30 days × Clear all

NCT05615636 2026-05-20

A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL

Phase 2 Recruiting

Hodgkin Disease, Lymphoma, B-Cell